+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Acute Lung Injury Treatment Market Report and Forecast 2023-2031

  • PDF Icon


  • 180 Pages
  • June 2023
  • Region: Global
  • Expert Market Research
  • ID: 5855147
The global acute lung injury treatment market was valued at USD 3.1 billion in 2022, driven by the increasing prevalence of aging population and advances in diagnostic techniques across the globe. The market size is anticipated to grow at a CAGR of 3% during the forecast period of 2023-2031 to achieve a value of USD 4 billion by 2031.

Acute Lung Injury Treatment: Introduction

Acute lung injury (ALI), also known as acute respiratory distress syndrome (ARDS), is a severe and life-threatening condition that affects the lungs. It is characterized by inflammation and damage to the alveoli (air sacs) in the lungs, leading to impaired oxygen exchange and difficulty in breathing. ALI can develop rapidly and is often associated with underlying medical conditions or injuries. Acute lung injury (ALI) is a significant global health concern, with varying incidence rates reported across different regions and populations. Here are some key epidemiological factors associated with ALI:
  • The incidence and prevalence of ALI can vary depending on the population studied and the underlying risk factors. ALI often occurs as a complication of other conditions, such as sepsis, pneumonia, trauma, or aspiration. The reported incidence rates of ALI range from 13 to 59 cases per 100,000 person-years, with higher rates observed in critically ill or hospitalized patients
  • ALI can affect individuals of all ages, but it is more commonly seen in older adults. The incidence of ALI increases with advancing age, with the highest rates observed in individuals over 65 years old. There is no significant gender difference in the incidence of ALI, as both males and females can be affected
  • Various risk factors contribute to the development of ALI. Sepsis, pneumonia, and aspiration of gastric contents are among the most common risk factors. Other factors include major trauma, inhalation injuries, severe systemic inflammation, and certain medical procedures. Understanding and addressing these risk factors are crucial in preventing and managing ALI

Key Trends in Global Acute Lung Injury Treatment Market

The global market for acute lung injury treatment is influenced by several key trends. Here are some of the key trends in the global acute lung injury market:
  • Increasing Incidence of Acute Lung Injury: There has been a rise in the incidence of acute lung injury globally. Factors such as increasing cases of pneumonia, sepsis, trauma, and complications arising from surgeries contribute to the growing prevalence of acute lung injury
  • Advancements in Ventilator Technology: Ventilators play a critical role in managing acute lung injury patients by providing mechanical ventilation support. Advancements in ventilator technology, including the development of advanced modes of ventilation, better monitoring capabilities, and improved patient-ventilator synchrony, are enhancing the management of acute lung injury cases and improving patient outcomes
  • Focus on Lung-Protective Ventilation Strategies: Lung-protective ventilation strategies have gained prominence in the management of acute lung injury. These strategies aim to minimize ventilator-induced lung injury and further lung damage by using lower tidal volumes, positive end-expiratory pressure (PEEP), and other protective measures
Global Acute Lung Injury Market Treatment Segmentations
The market can be categorised into therapy, injury type, end user and region.

Market Breakup by Therapy

  • Mechanical Ventilation
  • Pharmacotherapy
  • Fluid Management
  • Others

Market Breakup by Injury Type

  • Direct Injury
  • Indirect Injury

Market Breakup by End User

  • Hospitals
  • Speciality Centres
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Global Acute Lung Injury Market Treatment Overview

The global acute lung injury market has been experiencing steady growth due to various factors. The increasing prevalence of risk factors leading to ALI, such as sepsis and pneumonia, contributes to the growing incidence of the condition. Additionally, advancements in healthcare infrastructure, improved access to medical facilities, and rising awareness among healthcare professionals and patients have resulted in earlier diagnosis and treatment, driving market growth.

North America and Europe dominate the market due to well-established healthcare systems, advanced medical technologies, and high awareness of ALI among healthcare professionals. Asia Pacific is a rapidly growing market for ALI, driven by factors such as a large patient population, increasing healthcare expenditure, improving healthcare infrastructure, and rising awareness of critical care management. Latin America, the Middle East, and Africa are also emerging markets for ALI, where efforts are being made to enhance healthcare infrastructure and improve access to medical facilities.

Key Players in the Global Acute Lung Injury Treatment Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in global acute lung injury market are as follows:
  • Bayer AG
  • GSK plc
  • General Electric
  • Koninklijke Philips N.V
  • Linde plc
  • Medtronic
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
  • ONY Biotech Inc
  • Gilead Sciences, Inc
*The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Acute Lung Injury Treatment Market Overview
3.1 Global Acute Lung Injury Treatment Market Historical Value (2016-2022)
3.2 Global Acute Lung Injury Treatment Market Forecast Value (2023-2031)
4 Global Acute Lung Injury Treatment Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Global Acute Lung Injury Treatment Market Segmentation
5.1 Global Acute Lung Injury Treatment Market by Therapy
5.1.1 Market Overview
5.1.2 Mechanical Ventilation
5.1.3 Pharmacotherapy
5.1.4 Fluid Management
5.1.5 Others
5.2 Global Acute Lung Injury Treatment Market by Injury Type
5.2.1 Market Overview
5.2.2 Direct Injury
5.2.3 Indirect Injury
5.3 Global Acute Lung Injury Treatment Market by End User
5.3.1 Market Overview
5.3.2 Hospitals
5.3.3 Specialty Centres
5.3.4 Others
5.4 Global Acute Lung Injury Treatment Market by Region
5.4.1 Market Overview
5.4.2 North America
5.4.3 Europe
5.4.4 Asia Pacific
5.4.5 Latin America
5.4.6 Middle East and Africa
6 North America Acute Lung Injury Treatment Market
6.1 Market Share by Country
6.2 United States of America
6.3 Canada
7 Europe Acute Lung Injury Treatment Market
7.1 Market Share by Country
7.2 United Kingdom
7.3 Germany
7.4 France
7.5 Italy
7.6 Others
8 Asia Pacific Acute Lung Injury Treatment Market
8.1 Market Share by Country
8.2 China
8.3 Japan
8.4 India
8.6 Australia
8.7 Others
9 Latin America Acute Lung Injury Treatment Market
9.1 Market Share by Country
9.2 Brazil
9.3 Argentina
9.4 Mexico
9.5 Others
10 Middle East and Africa Acute Lung Injury Treatment Market
10.1 Market Share by Country
10.2 Saudi Arabia
10.3 United Arab Emirates
10.4 Nigeria
10.5 South Africa
10.6 Others
11 Patent Analysis
11.1 Analysis by Type of Patent
11.2 Analysis by Publication year
11.3 Analysis by Issuing Authority
11.4 Analysis by Patent Age
11.5 Analysis by CPC Analysis
11.6 Analysis by Patent Valuation
11.7 Analysis by Key Players
12 Grants Analysis
12.1 Analysis by year
12.2 Analysis by Amount Awarded
12.3 Analysis by Issuing Authority
12.4 Analysis by Grant Application
12.5 Analysis by Funding Institute
12.6 Analysis by NIH Departments
12.7 Analysis by Recipient Organization
13 Funding Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.5 Others
16 Supplier Landscape
16.1 Bayer AG
16.1.1 Financial Analysis
16.1.2 Product Portfolio
16.1.3 Demographic Reach and Achievements
16.1.4 Mergers and Acquisitions
16.1.5 Certifications
16.2 GSK plc.
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 General Electric
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 Koninklijke Philips N.V.
16.4.1 Financial Analysis
16.4.2 Financial Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 Linde plc
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 Medtronic
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Pfizer Inc.
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 Teva Pharmaceutical Industries Ltd.
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 ONY Biotech Inc.
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 Gilead Sciences, Inc.
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
17 Global Acute Lung Injury Treatment Market - Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
  • *Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • Bayer AG
  • GSK plc.
  • General Electric
  • Koninklijke Philips N.V.
  • Linde plc
  • Medtronic
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ONY Biotech Inc.
  • Gilead Sciences, Inc.



Table Information